Israel Yust

Medicine & Life Sciences

1. HIV 100%
2. Acquired Immunodeficiency Syndrome 56%
3. CD4 Lymphocyte Count 44%
4. HIV-1 43%
5. Antibodies 27%
6. Lymphocytes 25%
7. Erythrocytes 23%
8. HIV Infections 23%
9. Confidence Intervals 23%
10. Serum 23%
11. Israel 22%
12. Viral Load 21%
13. Antibody-Dependent Cell Cytotoxicity 20%
14. Highly Active Antiretroviral Therapy 20%
15. Therapeutics 18%
16. Mortality 17%
17. Incidence 17%
18. Pharmaceutical Preparations 16%
19. Antiphospholipid Syndrome 14%
20. Hemolysis 13%
21. Phagocytosis 12%
22. Cohort Studies 11%
23. Hypersensitivity 11%
24. Reverse Transcriptase Inhibitors 11%
25. Hepacivirus 11%
26. Protease Inhibitors 11%
27. Antigens 11%
28. Myocardial Infarction 10%
29. Chronic Renal Insufficiency 10%
30. Inappropriate ADH Syndrome 10%
31. abacavir 9%
32. Raltegravir Potassium 9%
33. Nevirapine 9%
34. Macrophage Inflammatory Proteins 9%
35. RNA 9%
36. Atazanavir Sulfate 9%
37. Autoimmunity 9%
38. Population 9%
39. Glomerular Filtration Rate 9%
40. Prospective Studies 8%
41. Anti-Idiotypic Antibodies 8%
42. Phagocytes 8%
43. Haemolytic Anaemia 8%
44. Immunoglobulin G 8%
45. Neoplasms 8%
46. efavirenz 8%
47. neutral lipid, phosphatidylcholine, phosphatidylethanolamine drug combination 7%
48. Ritonavir 7%
49. Infertility 7%
50. Blood Platelets 7%